Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children

Future Virology

Volumn 6, Issue 7, 2011, Pages 883-894

  Ray, Patricio E ^a   Hu, Chien An A ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

African American; APOL1; autophagic cell death; autophagy; Duffy antigen; genetic susceptibility; HIVAN; kidney failure; nonsynonymous SNP

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN L1; CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; GLYCOSPHINGOLIPID; MESSENGER RNA; NEF PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

AFRICA; CELL PROLIFERATION; CHILD; CHROMOSOME 22Q; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE COURSE; DISEASE PREDISPOSITION; EPITHELIUM CELL; FUNCTIONAL GENOMICS; GENE; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HISTOPATHOLOGY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNE RESPONSE; KIDNEY EPITHELIUM; KIDNEY FAILURE; MYH9 GENE; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS GENE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79960409785     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.57     Document Type: Review

References (106)

1. Strauss J, Abitbol C, Zilleruelo G et al. Renal disease in children with the acquired immunodeficiency syndrome. N. Engl. J. Med. 321(10), 625-630 (1989). (Pubitemid 19221305)
2. McCulloch MI, Ray PE. Kidney disease in HIV-positive children. Semin. Nephrol. 28(6), 585-594 (2008).
3. Rao TK, Filippone EJ, Nicastri AD et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 310(11), 669-673 (1984). (Pubitemid 14164641)
4. Pardo V, Aldana M, Colton RM et al. Glomerular lesions in the acquired immunodeficiency syndrome. Ann. Intern. Med. 101(4), 429-434 (1984). (Pubitemid 14018035)
5. Ray PE. Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy. Pediatr. Nephrol. 24(11), 2109-2119 (2009).
6. Levy JA. Discovery, structure, heterogeneity, and origins of HIV. In:HIV and the Pathogenesis of AIDS. (3rd Edition). Levy JA (Ed.).ASM Press, Washington, DC, USA, 1-26 (2007).
7. Zuo Y, Matsusaka T, Zhong J et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J. Am. Soc. Nephrol. 17(10), 2832-2843 (2006). (Pubitemid 44484673)
8. Rosenstiel PE, Gruosso T, Letourneau AM et al. HIV-1 Vpr inhibits cytokinesis in human proximal tubule cells. Kidney Int. 74(8), 1049-1058 (2008).
9. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J. Cereb. Blood Flow Metab. 27(1), 123-134 (2007). (Pubitemid 46006590)
10. Urbinati C, Nicoli S, Giacca M et al. HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. Blood 114(15), 3335-3342 (2009).
11. Pu H, Hayashi K, Andras IE, Eum SY, Hennig B, Toborek M. Limited role of COX-2 in HIV Tat-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. Brain Res. 1184, 333-344 (2007). (Pubitemid 350160577)
12. Feng X, Lu TC, Chuang PY et al. Reduction of Stat3 activity attenuates HIV-induced kidney injury. J. Am. Soc. Nephrol. 20(10), 2138-2146 (2009).
13. Husain M, Gusella GL, Klotman ME et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J. Am. Soc. Nephrol. 13(7), 1806-1815 (2002). (Pubitemid 34700605)
14. Greenway AL, McPhee DA, Allen K et al. Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J. Virol. 76(6), 2692-2702 (2002). (Pubitemid 34184855)
15. Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and Bcl-2-related family proteins. J. Am. Soc. Nephrol. 16(9), 2615-2625 (2005).
16. Rosenstiel P, Gharavi A, D'Agati V, Klotman P. Transgenic and infectious animal models of HIV-associated nephropathy. J. Am. Soc. Nephrol. 20(11), 2296-2304 (2009).
17. Sakurai N, Kuroiwa T, Ikeuchi H et al. Fluvastatin prevents podocyte injury in a murine model of HIV-associated nephropathy. Nephrol. Dial. Transplant. 24(8), 2378-2383 (2009).
18. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 40(10), 1175-1184 (2008).
19. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329(5993), 841-845 (2010).
20. Winkler CA, Nelson G, Oleksyk TK, Nava MB, Kopp JB. Genetics of focal segmental glomerulosclerosis and human immunodeficiency virus-associated collapsing glomerulopathy: the role of MYH9 genetic variation. Semin. Nephrol. 30(2), 111-125 (2010).
21. Liu XH, Hadley TJ, Xu L, Peiper SC, Ray PE. Up-regulation of Duffy antigen receptor expression in children with renal disease. Kidney Int. 55(4), 1491-1500 (1999). (Pubitemid 29157149)
22. Woolley IJ, Kalayjian R, Valdez H et al. HIV nephropathy and the Duffy antigen/receptor for Chemokines in African Americans. J. Nephrol. 14(5), 384-387 (2001). (Pubitemid 33080980)
23. Langhi DM Jr, Bordin JO. Duffy blood group and malaria. Hematology 11(5), 389-398 (2006). (Pubitemid 46957666)
24. Lee JS, Wurfel MM, Matute-Bello G et al. The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. J. Immunol. 177(11), 8086-8094 (2006). (Pubitemid 44846327)
25. Lachgar A, Jaureguiberry G, Le Buenac H et al. Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC).Biomed. Pharmacother. 52(10), 436-439 (1998). (Pubitemid 29356644)
26. Beck Z, Brown BK, Wieczorek L et al. Human erythrocytes selectively bind and enrich infectious HIV-1 virions. PLoS One 4(12), E8297 (2009).
27. Walton RT, Rowland-Jones SL. HIV and chemokine binding to red blood cells - DARC matters. Cell Host Microbe 4(1), 3-5 (2008). (Pubitemid 351958116)
28. He W, Neil S, Kulkarni H et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4(1), 52-62 (2008). (Pubitemid 351944053)
29. Horne KC, Li X, Jacobson LP et al. Duffy antigen polymorphisms do not alter progression of HIV in African Americans in the MACS cohort. Cell Host Microbe 5(5), 415-417; author reply 418-419 (2009).
30. Walley NM, Julg B, Dickson SP et al. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe 5(5), 408-410; author reply 418-409 (2009).
31. Winkler CA, An P, Johnson R, Nelson GW, Kirk G. Expression of Duffy antigen receptor for chemokines (DARC) has no effect on HIV-1 acquisition or progression to AIDS in African Americans. Cell Host Microbe 5(5), 411-413; author reply 418-419 (2009).
32. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat. Genet. 40(10), 1185-1192 (2008).
33. Bostrom MA, Freedman BI. The spectrum of MYH9-associated nephropathy. Clin. J. Am. Soc. Nephrol. 5(6), 1107-1113 (2010).
34. Kopp JB. Glomerular pathology in autosomal dominant MYH9 spectrum disorders: what are the clues telling us about disease mechanism? Kidney Int. 78(2), 130-133 (2010).
35. Sekine T, Konno M, Sasaki S et al. Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int. 78(2), 207-214 (2010).
36. Johnstone DB, Zhang J, George B et al. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Mol. Cell. Biol. 31(10), 2162-2170 (2011).
37. Genovese G, Tonna SJ, Knob AU et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int. 78(7), 698-704 (2010).
38. Tzur S, Rosset S, Shemer R et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128(3), 345-350 (2010).
39. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 283(31), 21540-21549 (2008).
40. Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 4(8), 1079-1082 (2008).
41. Smith EE, Malik HS. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res. 19(5), 850-858 (2009).
42. Duchateau PN, Pullinger CR, Orellana RE et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J. Biol. Chem. 272(41), 25576-25582 (1997). (Pubitemid 27438869)
43. Hartleben B, Godel M, Meyer-Schwesinger C et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest. 120(4), 1084-1096 (2010).
44. Wheeler RJ. The trypanolytic factor-mechanism, impacts and applications. Trends Parasitol. 26(9), 457-464 (2010).
45. Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 422(6927), 83-87 (2003). (Pubitemid 36323300)
46. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309(5733), 469-472 (2005). (Pubitemid 40994686)
47. Dickie P, Felser J, Eckhaus M et al. HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 185(1), 109-119 (1991).
48. Ray PE, Bruggeman LA, Weeks BS et al. bFGF and its low affinity receptors in the pathogenesis of HIV-associated nephropathy in transgenic mice. Kidney Int. 46(3), 759-772 (1994). (Pubitemid 24272034)
49. Kiryluk K, Martino J, Gharavi AG. Genetic susceptibility, HIV infection, and the kidney. Clin. J. Am. Soc. Nephrol. 2(Suppl. 1), S25-S35 (2007).
50. Chan KT, Papeta N, Martino J et al. Accelerated development of collapsing glomerulopathy in mice congenic for the HIVAN1 locus. Kidney Int. 75(4), 366-372 (2009).
51. Franks RR, Ray PE, Babbott CC et al. Maternal-fetal interactions affect growth of human immunodeficiency virus type 1 transgenic mice. Pediatr. Res. 37(1), 56-63 (1995).
52. Papeta N, Chan KT, Prakash S et al. Susceptibility loci for murine HIV-associated nephropathy encode trans-regulators of podocyte gene expression. J. Clin. Invest. 119(5), 1178-1188 (2009).
53. Reid W, Sadowska M, Denaro F et al. An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc. Natl Acad. Sci. USA 98(16), 9271-9276 (2001). (Pubitemid 32743906)
54. Ray PE, Liu XH, Robinson LR et al. A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy. Kidney Int. 63(6), 2242-2253 (2003). (Pubitemid 36605838)
55. Kline ER, Kleinhenz DJ, Liang B et al. Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration. Am. J. Physiol. Heart Circ. Physiol. 294(6), H2792-H2804 (2008).
56. Lassiter C, Fan X, Joshi PC et al. HIV-1 transgene expression in rats causes oxidant stress and alveolar epithelial barrier dysfunction. AIDS Res. Ther. 6, 1 (2009).
57. Otis JS, Ashikhmin YI, Brown LA, Guidot DM. Effect of HIV-1-related protein expression on cardiac and skeletal muscles from transgenic rats. AIDS Res. Ther. 5, 8 (2008).
58. Soler-Garcia AA, Johnson D, Hathout Y, Ray PE. Iron-related proteins: candidate urine biomarkers in childhood HIV-associated renal diseases. Clin. J. Am. Soc. Nephrol. 4(4), 763-771 (2009).
59. Paragas N, Nickolas TL, Wyatt C et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J. Am. Soc. Nephrol. 20(8), 1687-1692 (2009).
60. Soler-Garcia AA, Rakhmanina NY, Mattison PC, Ray PE. A urinary biomarker profile for children with HIV-associated renal diseases. Kidney Int. 76(2), 207-214 (2009).
61. Zhong J, Zuo Y, Ma J et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 68(3), 1048-1060 (2005). (Pubitemid 43246421)
62. Freedman BI, Kopp JB, Langefeld CD et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J. Am. Soc. Nephrol. 21(9), 1422-1426 (2010).
63. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95(2), 163-175 (1998). (Pubitemid 28473778)
64. Hanna Z, Priceputu E, Hu C, Vincent P, Jolicoeur P. HIV-1 Nef mutations abrogating downregulation of CD4 affect other Nef functions and show reduced pathogenicity in transgenic mice. Virology 346(1), 40-52 (2006). (Pubitemid 43254698)
65. Heckmann A, Waltzinger C, Jolicoeur P, Dreano M, Kosco-Vilbois MH, Sagot Y. IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS. Am. J. Pathol. 164(4), 1253-1262 (2004). (Pubitemid 38387792)
66. Hanna Z, Priceputu E, Chrobak P et al. Selective expression of human immunodeficiency virus Nef in specific immune cell populations of transgenic mice is associated with distinct AIDS-like phenotypes. J. Virol. 83(19), 9743-9758 (2009).
67. Rahim MM, Chrobak P, Hu C, Hanna Z, Jolicoeur P. Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphopenia. J. Virol. 83(22), 11830-11846 (2009).
68. Ray PE, Liu XH, Henry D et al. Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy. Kidney Int. 53(5), 1217-1229 (1998). (Pubitemid 28316882)
69. Ray PE, Tassi E, Liu XH, Wellstein A. Role of fibroblast growth factor- binding protein in the pathogenesis of HIV-associated hemolytic uremic syndrome. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290(1), R105-R113 (2006).
70. Argyris EG, Acheampong E, Nunnari G, Mukhtar M, Williams KJ, Pomerantz RJ. Human immunodeficiency virus type 1 enters primary human brain microvascular endothelial cells by a mechanism involving cell surface proteoglycans independent of lipid rafts. J. Virol. 77(22), 12140-12151 (2003). (Pubitemid 37339867)
71. Bobardt MD, Saphire AC, Hung HC et al. Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 18(1), 27-39 (2003). (Pubitemid 36120685)
72. Chen P, Chen BK, Mosoian A et al. Virological synapses allow HIV-1 uptake and gene expression in renal tubular epithelial cells. J. Am. Soc. Nephrol. 22(3), 496-507 (2011).
73. Hatsukari I, Singh P, Hitosugi N et al. DEC-205-mediated internalization of HIV-1 results in the establishment of silent infection in renal tubular cells. J. Am. Soc. Nephrol. 18(3), 780-787 (2007). (Pubitemid 46434495)
74. Mikulak J, Teichberg S, Faust T, Schmidtmayerova H, Singhal PC. HIV-1 harboring renal tubular epithelial cell interaction with T cells results in T cell trans-infection. Virology 385(1), 105-114 (2009).
75. Mikulak J, Teichberg S, Arora S et al. DC-specific ICAM-3-grabbing nonintegrin mediates internalization of HIV-1 into human podocytes. Am. J. Physiol. Renal Physiol. 299(3), F664-F673 (2010).
76. Mikulak J, Singhal PC. HIV-1 entry into human podocytes is mediated through lipid rafts. Kidney Int. 77(1), 72-73; author reply 73-74 (2009).
77. Khan F, Proulx F, Lingwood CA. Detergent-resistant globotriaosyl ceramide may define verotoxin/glomeruli-restricted hemolytic uremic syndrome pathology. Kidney Int. 75(11), 1209-1216 (2009).
78. Liu XH, Lingwood CA, Ray PE. Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease. Kidney Int. 55(2), 554-561 (1999). (Pubitemid 29082881)
79. Ray PE. Shiga-like toxins and HIV-1 'go through' glycosphingolipids and lipid rafts in renal cells. Kidney Int. 75(11), 1135-1137 (2009).
80. Lund N, Branch DR, Mylvaganam M et al. A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection. AIDS 20(3), 333-343 (2006).
81. Natoli TA, Smith LA, Rogers KA et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat. Med. 16(7), 788-792 (2010).
82. Green DF, Resnick L, Bourgoignie JJ. HIV infects glomerular endothelial and mesangial but not epithelial cells in vitro. Kidney Int. 41(4), 956-960 (1992).
83. Conaldi PG, Bottelli A, Wade-Evans A et al. HIV-persistent infection and cytokine induction in mesangial cells: a potential mechanism for HIV-associated glomerulosclerosis. AIDS 14(13), 2045-2047 (2000).
84. Khatua AK, Taylor HE, Hildreth JE, Popik W. Non-productive HIV-1 infection of human glomerular and urinary podocytes. Virology 408(1), 119-127 (2010).
85. Poulsom R, Little MH. Parietal epithelial cells regenerate podocytes. J. Am. Soc. Nephrol. 20(2), 231-233 (2009).
86. Suzuki T, Matsusaka T, Nakayama M et al. Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of cellular/collapsing focal segmental glomerulosclerosis. Am. J. Pathol. 174(5), 1675-1682 (2009).
87. Becker JU, Hoerning A, Schmid KW, Hoyer PF. Immigrating progenitor cells contribute to human podocyte turnover. Kidney Int. 72(12), 1468-1473 (2007). (Pubitemid 350197943)
88. Smeets B, Angelotti ML, Rizzo P et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J. Am. Soc. Nephrol. 20(12), 2593-2603 (2009).
89. Ronconi E, Sagrinati C, Angelotti ML et al. Regeneration of glomerular podocytes by human renal progenitors. J. Am. Soc. Nephrol. 20(2), 322-332 (2009).
90. Korgaonkar SN, Feng X, Ross MD et al. HIV-1 upregulates VEGF in podocytes. J. Am. Soc. Nephrol. 19(5), 877-883 (2008).
91. Conaldi PG, Bottelli A, Baj A et al. Human immunodeficiency virus-1 tat induces hyperproliferation and dysregulation of renal glomerular epithelial cells. Am. J. Pathol. 161(1), 53-61 (2002). (Pubitemid 34760770)
92. Doublier S, Zennaro C, Spatola T et al. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 21(4), 423-432 (2007).
93. Tang P, Jerebtsova M, Przygodzki R, Ray PE. Fibroblast growth factor-2 increases the renal recruitment and attachment of HIV-infected mononuclear cells to renal tubular epithelial cells. Pediatr. Nephrol. 20(12), 1708-1716 (2005). (Pubitemid 41722953)
94. Li Z, Jerebtsova M, Liu XH, Tang P, Ray PE. Novel cystogenic role of basic fibroblast growth factor in developing rodent kidneys. Am. J. Physiol. Renal Physiol. 291(2), F289-F296 (2006). (Pubitemid 44148118)
95. Ascherl G, Sgadari C, Bugarini R et al. Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability. AIDS Res. Hum. Retroviruses 17(11), 1035-1039 (2001). (Pubitemid 32881322)
96. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111(5), 707-716 (2003). (Pubitemid 36278589)
97. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358(11), 1129-1136 (2008). (Pubitemid 351398487)
98. Kumar D, Konkimalla S, Yadav A et al. HIV-associated nephropathy: role of mammalian target of rapamycin pathway. Am. J. Pathol. 177(2), 813-821 (2010).
99. Sharma M, Callen S, Zhang D, Singhal PC, Vanden Heuvel GB, Buch S. Activation of Notch signaling pathway in HIV-associated nephropathy. AIDS 24(14), 2161-2170 (2010).
100. Martinka S, Bruggeman LA. Persistent NF-kB activation in renal epithelial cells in a mouse model of HIV-associated nephropathy. Am. J. Physiol. Renal Physiol. 290(3), F657-F665 (2006). (Pubitemid 43724968)
101. Bruggeman LA, Nelson PJ. Controversies in the pathogenesis of HIV-associated renal diseases. Nat. Rev. Nephrol. 5(10), 574-581 (2009).
102. Chaparro AI, Mitchell CD, Abitbol CL et al. Proteinuria in children infected with the human immunodeficiency virus. J. Pediatr. 152(6), 844-849 (2008).
103. Longenecker CT, Scherzer R, Bacchetti P, Lewis CE, Grunfeld C, Shlipak MG. HIV viremia and changes in kidney function. AIDS 23(9), 1089-1096 (2009).
104. Post FA, Campbell LJ, Hamzah L et al. Predictors of renal outcome in HIV-associated nephropathy. Clin. Infect. Dis. 46(8), 1282-1289 (2008). (Pubitemid 351589915)
105. Judd A, Boyd KL, Stohr W et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24(4), 525-534 (2010).
106. Gordillo R, Kumar J, Del Rio M, Flynn JT, Woroniecki RP. Outcome of dialysis in children with human immunodeficiency virus infection. Pediatr. Nephrol. 24(1), 171-175 (2009).